Roth Capital Maintains Neutral on Tilray, Lowers Price Target to $4
Roth Capital analyst Scott Fortune maintains Tilray (NASDAQ:TLRY) with a Neutral and lowers the price target from $8 to $4.
Credit Suisse Maintains Outperform on JPMorgan Chase, Lowers Price Target to $145
Credit Suisse analyst Susan Roth Katzke maintains JPMorgan Chase (NYSE:JPM) with a Outperform and lowers the price target from $160 to $145.
Barclays Maintains Overweight on JPMorgan Chase, Lowers Price Target to $162
Barclays analyst Jason Goldberg maintains JPMorgan Chase (NYSE:JPM) with a Overweight and lowers the price target from $200 to $162.
Keefe, Bruyette & Woods Maintains Market Perform on SEI Investments, Lowers Price Target to $55
Keefe, Bruyette & Woods analyst Robert Lee maintains SEI Investments (NASDAQ:SEIC) with a Market Perform and lowers the price target from $62 to $55.
Piper Sandler Maintains Underweight on Ameriprise Financial, Lowers Price Target to $220
Piper Sandler analyst John Barnidge maintains Ameriprise Financial (NYSE:AMP) with a Underweight and lowers the price target from $231 to $220.
Piper Sandler Maintains Overweight on Virtus Investment, Lowers Price Target to $268
Piper Sandler analyst Sumeet Mody maintains Virtus Investment (NASDAQ:VRTS) with a Overweight and lowers the price target from $289 to $268.
Piper Sandler Maintains Overweight on Victory Capital Holdings, Lowers Price Target to $33
Piper Sandler analyst Sumeet Mody maintains Victory Capital Holdings (NASDAQ:VCTR) with a Overweight and lowers the price target from $35 to $33.
HC Wainwright & Co. Maintains Buy on Biotricity, Lowers Price Target to $2
HC Wainwright & Co. analyst Kevin Dede maintains Biotricity (NASDAQ:BTCY) with a Buy and lowers the price target from $6 to $2.
HC Wainwright & Co. Downgrades F-star Therapeutics to Neutral, Lowers Price Target to $7
HC Wainwright & Co. analyst Patrick Trucchio downgrades F-star Therapeutics (NASDAQ:FSTX) from Buy to Neutral and lowers the price target from $35 to $7.
Goldman Sachs Upgrades Allogene Therapeutics to Buy, Raises Price Target to $32
Goldman Sachs analyst Salveen Richter upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Buy and raises the price target from $9 to $32.